PeptidePedia The community reference

Talk:GL Biochem (Shanghai)

Discussion page·3 threads·1 archive

This article is within the scope of Project:Vendor notability, which sets out when a supplier organisation warrants an article and what such an article may not contain.
Supplier articles attract promotional editing. Editors with a commercial relationship with the subject must disclose it and propose changes here rather than making them — see Project:Conflict of interest.

This is the discussion page for the article GL Biochem (Shanghai). It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Supporter disclosure and article neutralityRfC

Request for comment. This discussion is advertised to the wider editorial community. Uninvolved editors are asked to comment on the question as framed in the opening statement, not on the conduct of the participants.

Request for comment. This organisation is one of the site's labelled supporters. The article is also, on the sourcing, one of the better-documented supplier articles — because the organisation's market position genuinely produces more complete certificates.

Question: how should the article handle the coincidence? Options: (a) disclose in the article and change nothing else; (b) disclose and have an uninvolved editor review every evaluative sentence; (c) suppress favourable observations to compensate; (d) delete the article. — RfC_Rasmus (talk) 10:41, 5 December 2024 (UTC)

(b). (c) is a neutrality violation in the opposite direction and (d) punishes the reader for our funding arrangements. (a) is nearly right but leaves us asserting our own neutrality without a check. A review by someone with no involvement in the article is cheap and it is exactly what the disclosure is for. — CoI_Corin (talk) 13:22, 5 December 2024 (UTC)

(b). I will add that the favourable observations here are unusually verifiable: "the certificate includes amino acid analysis" is a documentary fact about a document, not an assessment. Those are the safest kind of favourable statement and the article should prefer them over any characterisation. — NPOV_Nadia (talk) 09:36, 6 December 2024 (UTC)

(b), and the disclosure should sit in the article body where a reader will encounter it, not in a footnote. If we are asking to be trusted, the ask should be visible. — PuffRemoverPax (talk) 11:14, 7 December 2024 (UTC)

(b). One addition: the review should be recorded — who did it and when — so that the claim of independent review is itself checkable rather than asserted. — DisclosureDido (talk) 14:52, 9 December 2024 (UTC)

Closing: consensus for (b). Disclosure to sit in §Reception in the body; evaluative sentences reviewed by an uninvolved editor; the review recorded on this page. Preference for documentary facts over characterisations adopted as drafting guidance. — RfC_Rasmus (talk) 10:27, 14 December 2024 (UTC)

Standing note: what this article may not containResolved

Placing the standing note at the top of every supplier talk page so it does not have to be re-argued. Under Project:Vendor notability a supplier article may not contain: a price, an offer, a discount, a price list, any contact detail, or a shipping-outcome claim not attributed to a source.

Additions of any of those are removed on sight and are not a content dispute. — NPOV_Nadia (talk) 09:12, 4 July 2024 (UTC)

Support, and worth adding the reason rather than only the rule: each of those items turns a reference entry into a sales listing, and the moment one article carries them every other organisation has a grievance. — CoI_Corin (talk) 11:48, 4 July 2024 (UTC)

Support. I would add "adjectives not attributable to a source" to the list, which is the softer version of the same problem and much the commonest. — Hedgerow_Hal (talk) 10:23, 5 July 2024 (UTC)

Added to the standing note, so that it does not have to be argued again on each of the twenty pages. ✓ ResolvedNPOV_Nadia (talk) 08:57, 6 July 2024 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.
This page was last edited on 30 March 2025, by CDMO_Caradoc. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).